Earlier this week CNBC released an article after Stitch Fix’s earnings release with the following headline: “Stitch Fix shares crater as retailer cuts forecast, despite topping earnings estimates”.1 Below are some key points from the article as well as Stitch Fix’s FQ1 2022 Earnings Call (Dec 7th).2 


“The number of active customers using its services fell short of expectations, hinting at slowing demand. Specifically, a recent promotional offer resulted in a wave of new customers who briefly joined Stitch Fix but didn’t stick around.” - CNBC


“We launched a high dollar value referral program for new customers, which ultimately brought in clients who did not remain active as long as we had hoped… We have since ended the program. However, our net client adds were impacted by this in the first quarter, and we expect to continue to see the effects of this into the second quarter.” - Dan Jedda, CFO



Below is the chart with HundredX Stitch Fix Future Purchase Intent (Trailing 3 Months)

HundredX future purchase intent data from Stitch Fix consumers caught both the upswing in consumer purchase behavior associated with the promotional offering as well as the downswing that followed. This capture provided early insight into the initial success and transitory nature of the promotion.

Additional Stitch Fix Insights from HundredX Data


Future Purchase Intent vs E-commerce Competitors

 

HundredX data for Stitch Fix shows future purchase intent lags behind the rest of the e-commerce industry; however, a small uptick from October to November could be an early sign that new strategies by company management might be starting to pay dividends.

Drivers


HundredX data shows the top 7 most frequently selected drivers for Stitch Fix. The company generally performs well in its most important drivers, but consumers overwhelmingly dislike Stitch Fix’s prices.

 

Enterprise Narrative and Migration


How consumers are migrating to and from a company is a key data input into the enterprise narrative as it directly impacts a company's top line growth trajectory. 

Consumers that plan to spend/use more or about the same

in the next 12 months

Consumers that plan to spend/use less

in the next 12 months

HundredX data indicates the top positive drivers for customers planning to spend more or about the same at Stitch Fix in the next 12 months as well as those who plan to spend less at Stitch Fix in the next 12 months.  For those who plan to continue or expand their usage of Stitch Fix’s products, the core value proposition of Styles and Service (Ease of Use, Return Processes, and Delivery Speed) drive their usage.  However, for those planning to spend less, Price drives their decision process.

------------------------


1CNBC: Stitch Fix shares crater as retailer cuts forecast, despite topping earnings estimates


2Stitch Fix, Inc. (SFIX) Q1 2022 Earnings Call Transcript


This analysis is based on HundredX's proprietary data, developed from consumer feedback collected through the HundredX Causes Program. Nothing in the HundredX data constitutes professional or investment advice on the part of HundredX.


Strategy Made Smarter


HundredX works with a variety of companies and their investors to answer some of the most important strategy questions in business:

  • Where are customers "migrating"?
  • What are they saying they will use more of in the next 12 months?
  • What are the key drivers of their purchase decisions and financial outcomes?


Current clients see immediate benefits across multiple areas including strategy, finance, operations, pricing, investing, and marketing.


Our insights enable business leaders to define and identify specific drivers and decisions enabling them to grow their market share.


Please contact our team to learn more about which businesses across 75 industries are best positioned with customers and the decisions you can make to grow your brand’s market share.

Share This Article

06 May, 2024
Sure, lattes, mochaccinos, and cappuccinos are pricey, but they taste delicious. For many consumers, the great taste of coffee shop coffee made it worth the cost. But customers at Starbucks aren't so sure the tradeoff is worth it anymore. Examining more than 420,000 pieces of feedback across the Quick, Fast, Casual (QFC) industry, including over 21,000 on Starbucks, we find: Starbuck's Purchase Intent 1,2 is down 3% over the past six months, with most of that dip occurring over the past few months. By contrast, Dunkin' Donuts has remained within a tight range over the past six months, as did an average of other, smaller coffee chains. Customers increasingly see less value in Starbucks. Starbuck's Value perception 3 fell 5% over the past six months, compared to just 1% for Dunkin' Donuts. However, it also fell 5% for the average of the smaller coffee chains. Coffee drinkers feel significantly unhappier about Starbuck's quality and taste. Starbuck's Taste perception fell 4% over the past six months, while rising 1% for competitors. Likewise, its Quality perception dipped 3% over the same time period (and 8% over the year). Ultimately, Starbuck's perceived drop in taste is leading inflation-weary consumers to say they plan to spend less at the coffee chain, as the value just isn't as good.
06 May, 2024
Forbes Best Brands for Social Impact, Powered by HundredX
06 May, 2024
Ozempic once dominated the headlines, but GLP-1 competitor Mounjaro is winning over customers. GLP-1 drugs, used for treating diabetes and aiding in weight loss, are relatively new on the market yet have surged in popularity over the last year. They're becoming so popular that J.P. Morgan estimates that 30 million people in the US may be using a GLP-1 drug by 2030. This statistic presents a significant potential for early drug creator Novo Nordisk (Ozempic, Wegovy), and perhaps an even bigger one for Eli Lilly (Mounjaro, Zepbound). HundredX data indicates Eli Lilly is in a position to win over Novo Nordisk as Mounjaro's Usage Intent widens against the competition. Ozempic may have name recognition, but customers feel more positively about Mounjaro's effectiveness and lifestyle impact, even if they aren't excited about its high price. Examining 1,500 pieces of customer feedback across Mounjaro, Ozempic, and Wegovy, we find: GLP-1 users increasingly say they plan to use Mounjaro more, and Ozempic less . Mounjaro’s Usage Intent is up 19% since July, Wegovy’s is up 3%, and Ozempic has stayed within a tight range. Customers feel Mounjaro is more effective than competing drugs, but it’s harder to get . Mounjaro outperforms other GLP-1 drugs in effectiveness, lifestyle impact, and side effects. However, customers dislike its cost and availably more than competitors.
Share by: